$ISRG

Shopify (SHOP) and Intuitive Surgical (ISRG) have underperformed this year, with shares down 19% and 29% respectively. Shopify reported strong Q2 revenue of $3.6B, up 34% YoY, and positive guidance. Despite AI concerns, it is leveraging AI to enhance services. Intuitive Surgical faces competition but maintains a strong market lead in robotic surgery with its da Vinci system, benefiting from high switching costs and a large addressable market.

Abbott Laboratories (ABT) reported higher quarterly revenue than Intuitive Surgical (ISRG) over the last eight quarters, but ISRG grew revenue at a faster pace. ABT's revenue grew 19% from Q3 2024 to Q2 2026, while ISRG's revenue grew 45%. Both companies have steady revenue trajectories. ABT reported a 14% operating margin, ISRG 34%. ABT offers a 2.5% dividend yield.

Intuitive Surgical (ISRG) rose 2.38% to $377.94, outperforming major indices' declines. Its shares fell 6.43% over the past month. Analysts expect Q2 EPS of $2.61 (up 8.75% YoY) and revenue of $2.88B (up 14.98% YoY). The company has a Zacks Rank of #3 (Hold) and a Forward P/E of 34.39, higher than its industry average.

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

Goldman Sachs projects 6.5 million humanoid robots will be shipped globally by 2035, representing a $138 billion market opportunity. Companies like Tesla, TSMC, Teradyne, and NVIDIA are positioned to benefit, with some already showing significant revenue growth. A potential AI slowdown is cited as a risk to this forecast.

Intuitive Surgical reported Q2 system placements up 24% YoY in the U.S. and 12% internationally, with growth in ASCs and upgrades. China competition and tender delays persist, while Japan's reimbursement expansion may boost 2027 adoption. The company plans a 2027 Extended Use Instruments program and invests in new platforms. Revenue grew 21% YoY, with strong margins. ISRG expects procedure growth and upgrades to drive 2027 revenue.

Intuitive Surgical (ISRG) shares fell 5.84% to $374.48. Executive VP Mark Brosius sold 231 shares worth ~$90,777. The company plans a new Malaysia facility, creating 1,200 jobs by 2032. HSBC downgraded ISRG from Buy to Hold with a $931 target. ISRG's market cap is $132.3B, down 20.3% over 12 months.

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

Intuitive Surgical (ISRG) reported improved patient outcomes in a meta-analysis of 14 million da Vinci robotic-assisted surgeries, showing shorter hospital stays and fewer complications. The study compared da Vinci with laparoscopic and open surgery, potentially influencing hospital purchasing and surgeon adoption. ISRG's market value is approximately $129.5 billion, with its business tied to robotic surgery adoption.

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3